New gel targets Hard-to-Treat cancers in early trial

NCT ID NCT06143774

Recruiting now Disease control Sponsor: TaiRx, Inc. Source: ClinicalTrials.gov ↗

First seen Jan 07, 2026 · Last updated May 10, 2026 · Updated 19 times

Summary

This early-phase study tests an oral gel called TRX-920 in people with advanced solid tumors that no longer respond to standard treatments. The gel contains a chemotherapy drug that aims to shrink tumors with fewer side effects than the standard IV version. About 30 participants will help find the safest dose and see how well the drug works.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

China Medical University Hospital
RECRUITING

Taichung, Taiwan

Contact Phone: •••-•••-•••• Email: •••••@•••••
National Cheng-Kung University Hospital
RECRUITING

Tainan, Taiwan

Contact Phone: •••-•••-•••• Email: •••••@•••••
Taipei Medical University Hospital
RECRUITING

Taipei, Taiwan

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

ADVANCED SOLID TUMOR